What is claimed is:

- An empty sc-MHC class II molecule comprising a peptide binding groove and a class II β2 chain comprising at least one amino acid substitution or deletion.
- 2. The empty sc-MHC class II molecule of claim 1 further comprising an immunoglobin light chain constant region or fragment thereof.
- An empty sc-MHC class II molecule comprising a peptide binding groove and covalently linked immunoglobin light chain constant region or fragment.
- 4. A loaded sc-MHC molecule produced by contacting the empty sc-MHC class II molecule of claim 1, 2, or 3 with a presenting peptide under conditions which form a complex between the presenting peptide and the empty sc-MHC molecule.
- 5. A sc-MHC class II fusion protein comprising a recombinantly fused presenting peptide and a class II β2 chain comprising at least one amino acid substitution or deletion.
- 6. The sc-MHC class II fusion protein of claim 5 further comprising an immunoglobin light chair constant region or tragment thereof.
- A sc-MHC class II fusion protein comprising a recombinantly fused presenting peptide and a covalently linked immunoglobin light chain constant region or fragment.
- An empty sc-MHC class II molecule comprising a peptide-binding groove, wherein the molecule comprises covalently linked in sequence:

ď





- a) an MHC class II β1 chain or a presenting-peptide binding portion thereof,
- b) \a class II β2 chain, comprising at least one amino acid substitution or deletion,
 - c) a peptide linker sequence, and
- d) an MHC class II $\alpha 1\alpha 2$ chain or a presenting-peptide binding portion thereof.
- 9. The empty sc-MHC class II molecule of claim 8, wherein the class II β2 chain amino acid deletion is essentially all of the class II β2 chain.
- 10. The empty sc MHC class II molecule of claim 9 further comprising an immunoglobin light chain constant region fragment covalently linked to the MHC class II a 22 chain or the presenting-peptide binding portion thereof.
- 11. An empty sc-MHC class II molecule comprising a peptide-binding groove, wherein the molecule comprises covalently linked in sequence:
- a) an MHC class II β 1 β 2 chain or a presenting-peptide binding portion thereof,
 - b) a peptide linker sequence,
- c) an MHC class ILα1α2 chain or a presenting-peptide binding portion thereof, and
 - d) an immunoglobin light chain constant region fragment.
- 12. The empty sc-MHC class II molecule of claim 11, wherein the immunoglobin light chain constant region fragment is a murine or human Ck chain.
- 13. The empty sc-MHC class II molecule of claim 11, wherein the immunoglobin light chain constant region fragment is a murine or human $C\lambda$ chain.

ţ

- 14. A loaded sc-MHC molecule produced by contacting the empty sc-MHC class II molecule of claims 8 or 11 with a presenting peptide under conditions which form a complex between the presenting peptide and the empty sc-MHC class II molecule.
- 15. A sc-MHC class II fusion molecule comprising a peptide-binding groove, the sc-MHC class II fusion molecule comprising covalently linked in sequence:
 - a) a presenting peptide,
- b) an MHC class II β1 chain or a presenting-peptide binding portion thereof,
- c) an MHC class II β2 chain comprising at least one amino acid substitution or deletion
 - d) a peptide linker sequence; and
- e) an MHC class II α1α2 chain of a presenting-peptide binding portion thereof.
- 16. The sc MHC class II fusion molecule of claim 15, wherein the class II β2 chain deletion comprises deletion of at least 2, 5, 10, 25, 50, 60, 70, 80, 90 or greater amino acids of the class II β2 chain.
- 17. The sc-MHC class II fusion molecule of claim 16, wherein the class II $\beta 2$ chain amino acid deletion is essentially all of the class II $\beta 2$ chain.
- 18. The sc-MHC class II fusion molecule of claim 15, wherein the class II β 2 chain substituted comprises a substitution of 2, $\sqrt{5}$, 10, 25, 50, 60, 70, 80, 90 or greater amino acids of the class II β 2 chain.
- 19. The sc-MHC class II fusion molecule of claim 18, wherein the class II β 2 chain substitution comprises a Cys¹¹⁷ to Ser¹¹⁷ substitution.

- 20. The sc-MHC class II fusion molecule of claim 15 further comprising an immunoglobin light chain constant region fragment covalently linked to the MHC class II α1α2 chain or the presenting-peptide binding portion thereof.
- 21. A sc-MMC class II fusion molecule comprising a peptide-binding groove, wherein the fusion molecule comprises covalently linked in sequence:
 - a) a presenting peptide,
- b) an MHC class II β 1 β 2 chain or a presenting-peptide binding portion thereof
 - c) apeptide linker sequence,
- d) an MHC class II\alpha 2 chain or a presenting-peptide binding portion thereof, and
 - e) an immunoglobin/light chain constant region (Ig-C_L) or fragment.
- 22. The sc-MHC class II fusion molecule of claim 21, wherein the immunoglobin light chain constant region fragment is a murine or human Ck chain.
- 23. The empty sc-MHC class II molecule of claim 21, wherein the immunoglobin light chain constant region fragment is a murine or human $C\lambda$ chain.
- 24. The sc-MHC class II fusion molecule of claim 22 or 23 wherein the immunoglobin light chain constant region (Ig-C_i) fragment is between about 80 to 130, 90 to 120, or 100 to 110 amino acids in length.
- 25. An empty polyspecific MHC complex comprising an sc-MHC class following general formula:

5 (3)

[A-B¹-C¹] || [D-B²-C²]

wherein,

a) A represents at least one empty sc-MHC class II molecule, _ 112

b) B_1 , B_2 are each independently a joining molecule, the same or different,

c) C_1 , C_2 are each independently an effector molecule, the same or different or -H; and

d) D represents at least one empty sc-MHC class II molecule, ligand binding molecule or -H.

- 26. A polyspecific MHC complex comprising an empty sc-MHC class II molecule comprising a peptide binding groove, the complex being represented by the formulae A-B-C, B-A-C, or A-C-B, wherein A is at least one sc-MHC class II molecule, B is a joining molecule and C is an effector molecule or -H, provided that when the complex is represented by A-C-B, -C- is not -H.
- 27. A loaded polyspecific MHC complex formed by contacting the polyspecific MHC complexes of claim 25 or 26 with a presenting peptide under conditions which form a specific binding complex between the presenting peptide and at least one of the empty sc-MHC class II molecules.
- 28. A polyspecific MHC complex fusion molecule comprising an sc-MHC molecule with peptide binding groove, the complex being represented by the following formula:

John J

Supr.

[A-B²-C²] [D-B²-C²]

wherein,





- a) A represents at least one sc-MHC class II molecule comprising a recombinantly fused presenting peptide,
- b) B₁, B₂ are each independently a joining molecule the same or different,
- c) C_1 , C_2 are each independently an effector molecule, the same or different or -H; and
- d) D represents at least one, sc-MHC class II molecule comprising a recombinantly fused presenting peptide, ligand binding molecule or -H.
- 29. A polyspecific MHC fusion molecule comprising a sc-MHC class II molecule comprising a peptide binding groove, the complex being represented by the formulae: A-B-C, B-A-C, or A-C-B, wherein A is at least one sc-MHC class II molecule comprising a recombinantly fused presenting peptide, B is a joining molecule and C is an effector molecule or -H, provided that when the complex is represented by the formulae: A-C-B, -C- is not H.
- 30. A NA segment encoding the sc-MHC class II molecule of claim 1, 3, 5, or 7.
- 31. A DNA segment encoding at least a portion of the polyspecific MHC molecule of claim 22 and 26.
 - 32. A DNA vector comprising the DNA segments of claim 27.
 - 33. A DNA vector comprising the DNA segments of claim 29.
- 34. A method of manufacturing a sc-MHC class II molecule comprising a β2 class II chain modification, the method comprising:
- a) providing a cell comprising a DNA vector, wherein the DNA vector comprises DNA sequence encoding the sc-MHC class II molecule comprising the β2 class II chain modification,

Doy)

- culturing the cell in medium under conditions which permit expression of the sc-MHC class II molecule; and
 - c) \ purifying the sc-MHC class II molecule from the cell or medium.
- 35. The method of claim 34, wherein the sc-MHC class II molecule comprising the β 2 class II chain modification is the sc-MHC class II molecule recited in claim 1, 3,5 or 7.
- 36. A method of manufacturing a polyspecific MHC class II complex, the method comprising:
- a) providing a cell comprising one or more DNA vectors, which vectors comprise a DNA sequence encoding the polyspecific MHC complex or a portion thereof capable of specifically binding a joining molecule,
- b) culturing the cell in medium under conditions which permit expression of the polyspecific MHC molecule; and
 - c) purifying the polyspecific MHC molecule from the cell or medium.
- 37. A method of suppressing an immune response in a mammal comprising administering to the mammal an effective amount of the sc-MHC complex of claim 4, 5, 7, 17 or 28.

(20 as)